Suppr超能文献

大鼠肺和肾中由去亮氨酸10 - 血管紧张素I生成血管紧张素II及其他血管紧张素肽。

Formation of angiotensin II and other angiotensin peptides from des-leu 10-angiotensin I in rat lung and kidney.

作者信息

Drummer O H, Kourtis S, Johnson H

机构信息

University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia.

出版信息

Biochem Pharmacol. 1988 Nov 15;37(22):4327-33. doi: 10.1016/0006-2952(88)90614-4.

Abstract

The formation of AII from a metabolite of AI, des-leu10-angiotensin I [A(1-9)] has been studied in centrifugal fractions of rat lung and kidney using gradient elution HPLC to monitor the formation of peptide products. AII-forming activity was present in kidney S2 (22.3 nmol/mg protein/min) but not in kidney P2 centrifugal fractions. Lung S2 fractions showed relatively weak AII-forming activity (0.34 nmole/mg protein/min) whilst no activity was observed in lung P2. Carboxypeptidase N-like activity measured using both Hipp-Arg and Hipp-Lys as synthetic substrates did not parallel AII-forming activity, since this activity was highest in the P2 fractions of both lung and kidney, as were ACE and aminopeptidase activities. Whilst the major peptide produced in kidney S2 was AII (71%) significant amounts of both AIII (23%) and A(2-9) (6%) were also observed. In lung the amounts of these peptides produced as a percentage of the A(1-9) degrading activity were 2.9%, 2.4% and 21% respectively. The AII-forming activity in kidney S2 was not inhibited by enalaprilat, bestatin, amastatin, phosphoramidon or Pro-Phe but was inhibited (31%) by 1 mM cobalt (II). 1,10-Phenanthroline, iodoacetic acid, EDTA and puromycin significantly enhanced the formation of AII and increased the rate of degradation of the substrate, A(1-9). These results support the concept of a sequential carboxypeptidase pathway operating, particularly in kidney, to produce AII from AI. These results provide further evidence of an alternative metabolic pathway for the formation of AII not involving angiotensin converting enzyme.

摘要

利用梯度洗脱高效液相色谱法监测肽产物的形成,在大鼠肺和肾的离心组分中研究了由血管紧张素I(AI)的代谢产物去亮氨酸10 - 血管紧张素I [A(1 - 9)]形成血管紧张素II(AII)的过程。肾S2组分中存在AII形成活性(22.3纳摩尔/毫克蛋白/分钟),而肾P2离心组分中未检测到。肺S2组分显示出相对较弱的AII形成活性(0.34纳摩尔/毫克蛋白/分钟),而肺P2中未观察到活性。使用Hipp - Arg和Hipp - Lys作为合成底物测定的羧肽酶N样活性与AII形成活性不平行,因为该活性在肺和肾的P2组分中最高,血管紧张素转换酶(ACE)和氨肽酶活性也是如此。虽然肾S2中产生的主要肽是AII(71%),但也观察到了大量的血管紧张素III(AIII,23%)和A(2 - 9)(6%)。在肺中,这些肽的产生量占A(1 - 9)降解活性的百分比分别为2.9%、2.4%和21%。肾S2中的AII形成活性不受依那普利拉、抑肽酶、氨甲酰抑肽酶、磷酰胺脒或脯氨酰苯丙氨酸的抑制,但受到1 mM钴(II)的抑制(31%)。1,10 - 菲啰啉、碘乙酸、乙二胺四乙酸(EDTA)和嘌呤霉素显著增强了AII的形成,并提高了底物A(1 - 9)的降解速率。这些结果支持了一种顺序羧肽酶途径的概念,该途径尤其在肾脏中起作用,从AI产生AII。这些结果为不涉及血管紧张素转换酶的AII形成的替代代谢途径提供了进一步的证据。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验